It will be a hat-trick for Aratana Therapeutics Inc. (PETX) if Nocita, the company’s investigational local post-operative analgesia for cranial cruciate ligament surgery in dogs, secures the stamp of approval from the FDA’s Center for Veterinary Medicine on August 28, 2016.Administered as a single dose by tissue infiltration during closure of cranial cruciate ligament surgery in dogs, Nocita would provide a non-opioid alternative to provide sustained pain control for up to 72 hours post-surgery.If it passes the FDA muster, Nocita is expected to be commercially available to veterinarians in the fall of 2016.Galliprant, which received approval in March of this year, for the control of pain and inflammation associated with osteoarthritis in dogs, is the first product from Aratana’s pipeline to receive the green signal.Entyce, approved in May of this year, for appetite stimulation in dogs, is the company’s second new chemical entity to win FDA approval. Galliprant is expected to be available to veterinarians in fall 2016 while Entyce is expected to be launched in February 2017.